R ecent studies confirm the utility of unattended portable monitoring (PM) as a diagnostic option for suspected obstructive sleep apnea/hypopnea (OSAH) that is uncomplicated (ie, without other sleep or medical comorbidities) (1) (2) (3) (4) (5) (6) . Practice standards are required to guide appropriate clinical use of this new technology and to ensure that quality assurance standards are adhered to.
Recommendations for the use of unattended PM devices are predicated on the understanding that PM should be performed in conjunction with a comprehensive sleep evaluation and supervised by a physician trained in sleep medicine. When used appropriately, PM may expedite treatment when there is a high clinical suspicion of OSAH (1-3).
The three general settings for the use of PM in Canada are as follows: 1. Areas with acceptable wait times for a sleep medicine consultation and Level 1 sleep study. The present position paper on the use of portable monitoring (PM) as a diagnostic tool for obstructive sleep apnea/hypopnea (OSAH) in adults was based on consensus and expert opinion regarding best practice standards from stakeholders across Canada. These recommendations were prepared to guide appropriate clinical use of this new technology and to ensure that quality assurance standards are adhered to. Clinical guidelines for the use of PM for the diagnosis and management of OSAH as an alternative to in-laboratory polysomnography published by the American Academy of Sleep Medicine Portable Monitoring Task Force were used to tailor our recommendations to address the following: indications; methodology including physician involvement, physician and technical staff qualifications, and follow-up requirements; technical considerations; quality assurance; and conflict of interest guidelines. When used appropriately under the supervision of a physician with training in sleep medicine, and in conjunction with a comprehensive sleep evaluation, PM may expedite treatment when there is a high clinical suspicion of OSAH. Canadian Thoracic Society position paper should be implemented according to the practical needs and regulations of the local community. Ideally, however, any modification of the recommendations should be made in consultation with the local or regional sleep medicine specialists.
InDICATIonS
Complete laboratory polysomnography (Level 1) remains the gold standard for the evaluation of sleep-disordered breathing and is the test of choice when readily available. A summary of the levels of evaluations used for sleep testing depending on the types of monitoring devices are presented in Table 1 (1-3). PM studies can be used to confirm the diagnosis of OSAH in patients with a moderate to high pretest probability of this disorder based on clinical evaluation when integrated into a package of care that includes a comprehensive sleep evaluation by a qualified sleep physician and the back-up availability of polysomnography.
A PM device should not be used for screening of asymptomatic patients, for the evaluation of individuals with comorbid medical conditions (eg, pulmonary disease, neuromuscular disease or congestive heart failure) or those suspected of having other sleep disorders (eg, insomnia, periodic limb movement disorder or central sleep apnea). Portable monitoring as case selection for OSAH is not recommended for the pediatric population (children younger than 12 years of age). 
A MeDICAL evALuATIon AnD

post-test follow-up must include the following:
phySICIAn AnD TeChnICAL STAff RequIReMenTS
Minimum physician requirements to interpret portable tests
The ability to interpret PM studies is not limited by physician speciality, provided that the appropriate training and experience has been obtained and the physician is associated with an accredited sleep facility. Where there is no regional Level 1 sleep facility, interpreting physician collaboration with the nearest sleep centre is strongly recommended. 
TeChnICAL ConSIDeRATIonS
equipment
At minimum, the PM must record airflow (preferably via pressure transducer), respiratory movement and blood oxygenation (1-3). Level 3 monitoring devices that use a minimum of four channels including one respiratory movement, one airflow and one electrocardiogram/heart rate and one oxygen saturation channel are preferred over devices that monitor fewer variables (ie, Type 4, peripheral arterial tone or oximetry alone).
The use of Level 4 studies, or using oximetry alone, has significant limitations in distinguishing between different types of sleep-disordered breathing, which must be fully appreciated before they are used to make diagnostic decisions.
Level 3 studies (with three or more channels including oximetry and heart rate) are recommended over Level 4 studies or oximetry alone. Many Type 3 devices are commercially available and it is recommended that validated and reliable (data loss of less than 10%) PM equipment be used.
A post-test questionnaire should include time of lights off and lights on, the patient's estimated total sleep time, any unusual occurrences and whether the night with the PM was representative. Scoring and interpretation of pM testing: PM devices must allow for the display of raw data for manual scoring by trained and qualified technical staff (See section 4.2). There should be documented training and quality assurance with inter-rater reliability checks (see item 6) for all scoring staff. Scoring criteria should be consistent with current published • American Academy of Sleep Medicine standards for the scoring of apneas and hypopneas (9) . Apnea and hypopnea definition: Where other definitions are • used for scoring hypopneas (eg, [10] ), these criteria should be identified in the report with the relevant reference. A qualified physician (see section 4.1) must report the study • results after reviewing the raw and scored data from the PM together with the accompanying clinical data. The Physician report should include comment on and/or • confirm the following:
performing the test
i. Pre-and post-test sleep questionnaires and their impact on test validity; ii. Pre-test probability estimate of OSAH; iii. Potential confounding effect of medical comorbidities and medications; iv. Technical quality of study; v. Presence of snoring (if available on recording); vi. Heart rate abnormalities; vii. Severity of the OSAH, if present; viii. The severity of desaturations and the validity of these parameters if they are in question; ix. Presence and potential significance, or lack thereof, of central and mixed respiratory events; x. Respiratory patterns that may be artifactual, or suggest a complicated sleep apnea syndrome and/or hypoventilation; xi. Possible differential diagnosis for nonspecific oximetry patterns; xii. Suggestions for further investigations and management; xiii. Highlight critically abnormal test results or results that may need further diagnostic clarification (see section 5.3). 
Test follow-up
quALITy MAnAGeMenT pRoGRAM
Facilities performing PM require a quality management program that includes -but is not limited to -the following: Establishing routine inter-rater reliability checks of the • technologist scoring of records; Establishing routine inter-rater reliability checks of the • physicians' interpretation of records; Establishing a mechanism for a minimum of quarterly reviews • of 10 randomly selected records of original data from PM tests performed by the facility to establish whether the tests were properly performed and that the test results are reliable; Surveying patients periodically to determine their satisfaction • with the PM services provided by the facility and to seek their suggestions for improvements; and Surveying referring physicians periodically to determine • their satisfaction with the PM services provided by the facility.
ConfLICT of InTeReST GuIDeLIneS
Ideally, no aspect of PM for the purposes of diagnostic testing and/or treatment including, but not limited to, the delivery and/or pick-up of the device should be performed by a vendor of CPAP units, durable medical equipment supplier or other goods that may be sold based on results of the PM test. However, given the limitation in available medical and facility resources, some communities may have to rely on third-party home care suppliers for a variable degree of PM testing. In these circumstances, the standard of care presented in the current guidelines should be maintained, and full disclosure of any conflict of interest must be made clear to the patients and referring physician by written public disclosure.
ConCLuSIon
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